FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer – The ASCO Post

By The ASCO Post StaffPosted: 12/19/2019 7:53:00 AM Last Updated: 12/19/2019 3:53:34 PM On December 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev) for adult patients with locally advanced or metastatic urothelial cancer who have…

Read the full article here

Related Articles